Carlos Muete - Avicanna SVP Devel

All Insiders . USA . 
Stock . Avicanna . Stakeholders . Insider . Carlos Muete
AVCNF Stock  USD 0.25  0.04  19.05%   

Insider

Carlos Muete is SVP Devel of Avicanna
Phone647 243 5283
Webhttps://www.avicanna.com

Avicanna Management Efficiency

The company has return on total asset (ROA) of (0.2211) % which means that it has lost $0.2211 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.6898) %, meaning that it generated substantial loss on money invested by shareholders. Avicanna's management efficiency ratios could be used to measure how well Avicanna manages its routine affairs as well as how well it operates its assets and liabilities.
Avicanna has accumulated 415.83 K in total debt with debt to equity ratio (D/E) of 0.31, which is about average as compared to similar companies. Avicanna has a current ratio of 0.88, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Avicanna until it has trouble settling it off, either with new capital or with free cash flow. So, Avicanna's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Avicanna sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Avicanna to invest in growth at high rates of return. When we think about Avicanna's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 9 records

INSIDER Age

Jorge ValderramaGenomma Lab Internacional
N/A
Daniel NeriaGenomma Lab Internacional
N/A
Mximo JudaGenomma Lab Internacional
N/A
Juan SparvieriGenomma Lab Internacional
N/A
Marianne VelascoGenomma Lab Internacional
N/A
L PorresGenomma Lab Internacional
N/A
Engineer GallandGenomma Lab Internacional
N/A
Alejandro PatioGenomma Lab Internacional
N/A
Efran CrdovaGenomma Lab Internacional
N/A
Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research and development of evidence-based products for consumer medical and pharmaceutical segments worldwide. Avicanna Inc. was incorporated in 2016 and is headquartered in Toronto, Canada. Avicanna operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 124 people. Avicanna [AVCNF] is traded as part of a regulated electronic over-the-counter service offered by the NASD.

Management Performance

Return On Equity-1.69
Return On Asset-0.22

Avicanna Leadership Team

Elected by the shareholders, the Avicanna's board of directors comprises two types of representatives: Avicanna inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Avicanna. The board's role is to monitor Avicanna's management team and ensure that shareholders' interests are well served. Avicanna's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Avicanna's outside directors are responsible for providing unbiased perspectives on the board's policies.
Mba BEcon, CEO CoFounder
Roland Alvarez, SVP Operations
Frantz Devedec, Ex RD
Caitlin Johnston, VP Access
Ivana Maric, Ex Marketing
Carlos Muete, SVP Devel

Avicanna Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Avicanna a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity-1.69
Return On Asset-0.22
Operating Margin(2.11) %
Current Valuation20.15 M
Shares Outstanding74.52 M
Shares Owned By Insiders22.52 %
Price To Book9.32 X
Price To Sales4.51 X
Revenue3.27 M
Gross Profit2.83 M

Currently Active Assets on Macroaxis

TITANTitan Company Limited
UUnity Software
PAYCPaycom Soft
HBIHanesbrands
STLDSteel Dynamics

Other Information on Investing in Avicanna OTC Stock

Avicanna financial ratios help investors to determine whether Avicanna OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Avicanna with respect to the benefits of owning Avicanna security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY